Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study
The course of clinical management in chronic myeloid leukemia (CML) often faces a road-block in the form of front-line (imatinib) therapy resistance. Subsequently, several hotspot mutations were clinically validated in the kinase domain (KD) of BCR-ABL1, in deterring imatinib sensitivity and further...
Main Authors: | Samya Dey, Soumi Basu, Shahena Shah, Debmalya Bhattacharyya, Partha Pratim Gupta, Mahasweta Acharjee, Susanta Roychoudhury, Somsubhra Nath |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222001265 |
Similar Items
-
Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels
by: Hana Klamová, et al.
Published: (2013-04-01) -
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01) -
Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01) -
Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01) -
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)